Pages that link to "Q41719188"
Jump to navigation
Jump to search
The following pages link to Plasma and metabolic abnormalities in Gaucher's disease. (Q41719188):
Displaying 50 items.
- Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates (Q24312107) (← links)
- Dental profile of patients with Gaucher disease (Q24794388) (← links)
- Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease (Q26783393) (← links)
- The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement (Q28182540) (← links)
- Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease (Q33323654) (← links)
- Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease (Q33348492) (← links)
- Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience (Q33376274) (← links)
- Splenomegaly, cardiomegaly, and osteoporosis in a child with Gaucher disease (Q33401282) (← links)
- Gaucher's disease diagnosed by splenectomy. (Q33401608) (← links)
- Hemorrhagic aspects of Gaucher disease (Q33418647) (← links)
- Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model (Q33891532) (← links)
- Bone events and evolution of biologic markers in Gaucher disease before and during treatment (Q34153094) (← links)
- Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy (Q34281044) (← links)
- Gaucher disease and its treatment options (Q34386658) (← links)
- Gaucher disease: clinical profile and therapeutic developments (Q34443517) (← links)
- Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses (Q34471620) (← links)
- Clinically relevant therapeutic endpoints in type I Gaucher disease. (Q34471681) (← links)
- Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity (Q34479337) (← links)
- Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring (Q34623578) (← links)
- Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies (Q35028532) (← links)
- Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention (Q35153233) (← links)
- Future perspectives for glycolipid research in medicine (Q35153243) (← links)
- Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring (Q35608258) (← links)
- Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease (Q35768951) (← links)
- Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models (Q36136923) (← links)
- New developments in treating glycosphingolipid storage diseases. (Q36363837) (← links)
- The biology of the Gaucher cell: the cradle of human chitinases. (Q36597948) (← links)
- Role of chitotriosidase (chitinase 1) under normal and disease conditions (Q36630259) (← links)
- Oral aspects of Gaucher's disease: a literature review and case report. (Q36775633) (← links)
- Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response (Q36938544) (← links)
- Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. (Q37153186) (← links)
- Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring (Q37176146) (← links)
- Gaucher disease: a model disorder for biomarker discovery (Q37579908) (← links)
- Lysosomal storage disease: revealing lysosomal function and physiology. (Q37739706) (← links)
- The cellular pathology of lysosomal diseases (Q37944549) (← links)
- Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm (Q38240658) (← links)
- Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries (Q39275155) (← links)
- Substrate reduction therapy of glycosphingolipid storage disorders. (Q40317796) (← links)
- Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis (Q41962092) (← links)
- Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy (Q44163800) (← links)
- Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy (Q46102642) (← links)
- Current development and usefulness of biomarkers for Gaucher disease follow up (Q46785228) (← links)
- Rapid screening for lipid storage disorders using biochemical markers. Expert center data and review of the literature (Q47228432) (← links)
- Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment (Q47805142) (← links)
- Gaucher's disease. (Q52378279) (← links)
- Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. (Q53807595) (← links)
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. (Q53912470) (← links)
- Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages (Q60934934) (← links)
- La maladie de Gaucher chez l’enfant : mode de révélation, évolution naturelle, apports du traitement par l’enzyme de remplacement (Q61758343) (← links)
- [Biomarkers in Gaucher disease: up-to-date] (Q83374322) (← links)